Changes in Digoxin Pharmacokinetics Treated with Lipopolysaccharide in Wistar Rats
Ryuji KATO ministration of digoxin but had free access to water. Digoxin was administered intravenously after physiological saline (2.5 ml/kg, i.p.) administration in the control group and was administered intravenously on Day 1-3, and Day 5 after LPS (5 mg/kg, i.p.) administration in the LPS (ϩ) group. Blood samples (0.5 ml) were collected from the cervical vein under anesthesia with diethyl ether just before and 2 min, 5 min, 10 min, 30 min, 1 h, 2 h, 4 h, and 6 h after digoxin administration. Blood samples were transferred to a tube containing 5 units of heparin and centrifuged (600ϫg, 15 min). Resultant plasma was obtained and stored at 4°C until analysis.
Digoxin Pharmacokinetics after Oral Administration Digoxin solution (0.1 mg/ml) for administration was prepared in physiological saline and administered at a dose of 0.1 mg/kg. In the control group, digoxin was administered orally after physiological saline (2.5 ml/kg, i.p.) administration. In the LPS (ϩ) group, digoxin was given orally on Day 1-3, and Day 5 after LPS (5 mg/kg, i.p.) administration. Blood samples (0.5 ml) were collected from the cervical vein under anesthesia with diethyl ether just before and 1, 2, 4, 6, 8, 12, and 24 h after digoxin administration. Plasma was obtained by the method described in the section on intravenous administration.
Absorption from the Intestinal Loop A closed-loop was prepared in the LPS (ϩ) group on Day 1-3, and Day 5 after LPS (5 mg/kg, i.p.) administration. The absorption of digoxin was evaluated under anesthesia with urethane (1.5 g/kg, i.p.). The abdomen was opened by midline incision and the portal vein was cannulated to draw blood samples. About 16 cm of the lower portion of the ileum was selected. The segment was internally washed with saline and the distal end was ligated with thread. A needle attached to a syringe for drug administration was inserted through the proximal end and ligated with thread over the tissue to produce a closed intestinal loop. Digoxin solution (50 mM [ϭ39 mg/ml]) for administration was prepared in physiological saline, and 1 ml of the solution was administered. After the administration of digoxin, the needle was removed and the ligation was secured. Blood samples (0.2 ml) were collected from the portal vein at 30 min, 45 min, 1 h, 2 h, and 4 h after digoxin administration. Plasma was obtained by the method described in the section on intravenous administration.
Measurement of Digoxin Deproteinizing agent (200 ml, Abbott Laboratories, Abbott Park, IL, U.S.A.) was added to 200 ml of each plasma sample, mixed with a vortex mixer for 30 s, and centrifuged (600ϫg, 5 min). Digoxin was assayed using a fluorescence polarization immunoassay (FPIA: TDx Digoxin ® , Abbott Laboratories, IL, U.S.A.). A dilution method was used to measure digoxin concentration between 0.5 ng/ml and 150 ng/ml.
Pharmacokinetic Analysis The plasma concentration (Cp) versus time (t) profiles of digoxin were analyzed by a two-compartment model with first-order absorption, where the plasma concentrations after intravenous administration (without absorption) and after oral administration (with absorption) are described by Eqs. 1 and 2, respectively, as follows: 
(8) 
RESULTS

Changes in Body Temperature and Blood Pressure
Body temperature and blood pressure remained almost constant (39.1Ϯ0.5°C, 90.4Ϯ3.56 mmHg) throughout the period of experimentation in the control group. In the LPS (ϩ) group, body temperature and blood pressure decreased markedly (37.1Ϯ0.6°C and 80.6Ϯ16.9 mmHg, respectively) at 3 h after LPS administration (pϽ0.05) and tended to return to baseline thereafter. There were no significant betweengroup differences in temperature (Fig. 1a) or blood pressure (Fig. 1b) at 6, 9, and 12 h after LPS administration.
Changes in Plasma TNF-a a and IL-1b b Concentrations Plasma TNF-a and IL-1b increased significantly in the LPS (ϩ) group (pϽ0.05), peaking at 3 and 6 h, respectively, after
LPS administration. There were no significant betweengroup differences in plasma TNF-a level at 9 and 12 h after LPS treatment (Fig. 2a) and no between-group differences in plasma IL-1b at 12 h after LPS treatment (Fig. 2b) .
Disposition after Intravenous Administration
The concentration profiles were well described by the two-compartment model (Fig. 3) , and pharmacokinetic parameters are summarized in Table 1 . Compared with the control group, AUC i.v. was significantly increased in the LPS (ϩ) group (pϽ0.05 on Day 1-3; pϽ0.01 on Day 5). There were no significant between-group differences in V 1 but significant differences in V 2 on Day 1-3 (pϽ0.05).
Digoxin Pharmacokinetics after Oral Administration The concentration profiles were well described by the twocompartment model with first-order absorption (Fig. 4) , and pharmacokinetic parameters are summarized in Table 1 . Compared with the control group, there were no betweengroup differences in K a though AUC p.o. increased significantly in the LPS (ϩ) group (pϽ0.05 on Day 1-2).
Absorption from the Intestinal Loop Compared with the control group, AUC loop was significantly increased (pϽ0.05 on Day 2-3, and Day 5; pϽ0.01 on Day 1). C max was significantly increased in the LPS (ϩ) group on Day 1-2 (pϽ0.01) (Fig. 5, Table 2 ).
DISCUSSION
This study used LPS from E. coli as an inducer of endotoxemia. Though LPS (5 mg/kg, i.p.) was able to induce endotoxemia in all rats, all rats survived in this study. This dose (the equivalent of 10 9 bacterial cells) is thought to be sufficient to cause severe SIRS in humans.
In this study, body temperature and blood pressure decreased until 3 h after LPS administration and gradually returned to pre-administration levels by 12 h (Fig. 1) . These results were similar to those previously reported.
18) It has been reported that LPS stimulates monocytes/macrophages, activates NF-kB in these cells, and subsequently stimulates the production of pro-inflammatory cytokines such as TNF-a and IL-1b. [19] [20] [21] In the present study, serum TNF-a and IL1b increased transiently at 3 and 6 h, respectively, after LPS administration, and then decreased to pre-administration levels by 12 h after LPS administration (Fig. 2) . In the control group, serum IL-1b was slightly increased at 9 h. The increase of IL-1b may have been due to repeated blood collection with a needle. This difference between TNF-a and IL1b has been previously reported 2) and may indicate that LPS induced TNF-a before IL-1b induction via a TNF-a-mediated pathway. Since these findings were similar to those in previous reports of endotoxemia, 2, 18) a model of reversible and transient endotoxemia was successfully established in Wistar rats using LPS (from E. coli, 5 mg/kg, i.p.) in this study.
The pharmacokinetics of digoxin in pathophysiological conditions were examined in this model. Digoxin is a cardiac glycoside widely used as a therapeutic agent for tachycardiac atrial arrhythmia (such as atrial fibrillation) and congestive heart failure. 22) In this study, digoxin was used as a probe drug for a two-compartment model, and administered (Fig. 3 , Table 1 ). Although there were no significant between-group differences in V 1 , there were significant decreases in V 2 on Day 1-3 after LPS administration. However, b (elimination rate constant) remained relatively unchanged throughout the experiment, even after LPS treatment. The pharmacokinetics of digoxin is well described by a two-compartment model, and digoxin has a large V 2 (high tissue distribution). It appears that increase of AUC i.v. is due to decrease of V 2 .
After oral administration of digoxin, the AUC p.o. of digoxin in the LPS (ϩ) group increased significantly on Day 1-2 after LPS administration (Fig. 4, Table 1 ). However, b remained relatively unchanged throughout the experiment, even after LPS treatment. These findings suggested that the amount of digoxin absorption increases and the volume of distribution decreases.
Then we examined gastrointestinal permeability using an in situ closed-loop method. Plasma digoxin level increased significantly and AUC loop increased throughout the experiment after LPS administration, suggesting that increase in digoxin absorption by the small intestine plays an important role in the above increases (Fig. 5 , Table 2 ). In rats, cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp) in intestine are involved in digoxin absorption and metabolism. 23, 24) Decreases in intestinal CYP3A2 and P-gp may accompany these changes. In the pathologic state induced by LPS (5 mg/kg, i.p.), the excretion phase was not affected, but the absorption phase was greatly affected.
In conclusion, the present study showed that digoxin absorption was increased and the volume of distribution of the tissue compartment decreased after LPS administration (5 mg/kg, i.p.). It appears that digoxin pharmacokinetics recover over 3 d after LPS administration.
